FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3100891808> ?p ?o ?g. }

• W3100891808 abstract "Background NJH395 is a first-in-class immune stimulator antibody conjugate (ISAC) consisting of a toll-like receptor 7 (TLR7) agonist conjugated to an anti-HER2 antibody. Antibody-mediated delivery of TLR7 may limit systemic toxicities previously seen with TLR agonists, while enhancing long-lasting antitumor immune response. In preclinical studies, NJH395 showed promising activity in HER2 expressing xenograft mouse models, and demonstrated immunogenicity and cytokine release in mice and nonhuman primates. Methods This phase 1, first-in-human, open-label, multicenter study ( NCT03696771 ) is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of NJH395 in patients with nonbreast HER2+ advanced malignancies. The study design includes two parts: single-ascending dose (SAD), followed by multiple-ascending dose. Primary endpoint is safety; key secondary endpoints include assessment of pharmacokinetics, immunogenicity, and overall response rate. Tumor response was evaluated 3 weeks after treatment in SAD. Evaluation of pharmacodynamic markers including tumor-infiltrating lymphocytes is the key exploratory objective. Results Here, we report the results of the SAD part of this phase 1 study. As of July 01, 2020, 18 patients (10 males, 8 females; median age, 52.5 years [range, 42–74 years]) were enrolled in 5 dose cohorts (0.1–1.6 mg/kg). The tumor types included HER2+ colorectal cancer (N=11), gastroesophageal adenocarcinoma (N=2), non–small cell lung cancer (N=1), nasopharynx adenocarcinoma (N=1), pancreatic adenocarcinoma (N=1), bladder cancer (N=1), and small intestine adenocarcinoma (N=1). Seventeen patients reported 124 treatment-related adverse events. The most common (occurring in ≥ 20%) adverse events (AEs) of any grade (G), regardless of study drug relationship were cytokine release syndrome (55.6%, G ≤ 2), pyrexia (44.4%), nausea (44.4%), vomiting (33.3%), headache (33.3%), increased aspartate aminotransferase (AST, 33.3%), increased alanine aminotransferase (ALT, 27.8%), and lymphopenia/lymphocyte count decrease (27.8%). The most common ≥ G3 AEs (occurring in ≥ 10%) were lymphopenia/lymphocyte count decrease (27.8%) and increased AST (11.1%). Five dose-limiting toxicities, all G3, were reported in 3 patients: 2 cases of AST increase (1 at 0.2 mg/kg; 1 at 1.6 mg/kg), 1 ALT increase (1.6 mg/kg), 1 aseptic meningitis (1.6 mg/kg), and 1 meningism (1.6 mg/kg). No complete/partial response was seen; 9 patients had stable disease by RECIST v1.1 at 3 weeks post treatment. An increase in CD8-positive T-cells was detected in on-treatment tumor biopsies in 5 patients. Pharmacokinetics showed a greater than dose proportional exposure of NJH395; anti-drug antibodies were detected in all tested patients (14/14). Conclusions Single dosing of NJH395 showed significant but manageable toxicities in patients with nonbreast HER2+ advanced malignancies. Biomarker analysis is ongoing. Acknowledgements The authors thank all patients who participated in the study. The authors acknowledge Kavita Garg, PhD of Novartis Healthcare Pvt Ltd for providing medical editorial assistance with this abstract. Trial Registration ClinicalTrials. gov Identifier: NCT03696771 Ethics Approval The study was performed in accordance with ethical principles of the declaration of Helsinki and good clinical practice guidelines. The protocol and its amendments were approved by institutional review boards of each participating site. Consent Written informed consent was obtained from each patient prior to enrolment in the study." @default.
• W3100891808 created "2020-11-23" @default.
• W3100891808 creator A5001115937 @default.
• W3100891808 creator A5005038640 @default.
• W3100891808 creator A5014254979 @default.
• W3100891808 creator A5020173185 @default.
• W3100891808 creator A5031031537 @default.
• W3100891808 creator A5044064524 @default.
• W3100891808 creator A5052823826 @default.
• W3100891808 creator A5060366426 @default.
• W3100891808 creator A5071800834 @default.
• W3100891808 creator A5075336471 @default.
• W3100891808 date "2020-11-01" @default.
• W3100891808 modified "2023-10-18" @default.
• W3100891808 title "378 A first in-human, multicenter, open-label, dose-finding phase 1 study of the immune stimulator antibody conjugate NJH395 in patients with nonbreast HER2+ advanced malignancies" @default.
• W3100891808 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0378" @default.
• W3100891808 hasPublicationYear "2020" @default.
• W3100891808 type Work @default.
• W3100891808 sameAs 3100891808 @default.
• W3100891808 citedByCount "2" @default.
• W3100891808 countsByYear W31008918082022 @default.
• W3100891808 countsByYear W31008918082023 @default.
• W3100891808 crossrefType "proceedings-article" @default.
• W3100891808 hasAuthorship W3100891808A5001115937 @default.
• W3100891808 hasAuthorship W3100891808A5005038640 @default.
• W3100891808 hasAuthorship W3100891808A5014254979 @default.
• W3100891808 hasAuthorship W3100891808A5020173185 @default.
• W3100891808 hasAuthorship W3100891808A5031031537 @default.
• W3100891808 hasAuthorship W3100891808A5044064524 @default.
• W3100891808 hasAuthorship W3100891808A5052823826 @default.
• W3100891808 hasAuthorship W3100891808A5060366426 @default.
• W3100891808 hasAuthorship W3100891808A5071800834 @default.
• W3100891808 hasAuthorship W3100891808A5075336471 @default.
• W3100891808 hasBestOaLocation W31008918081 @default.
• W3100891808 hasConcept C111113717 @default.
• W3100891808 hasConcept C112705442 @default.
• W3100891808 hasConcept C121608353 @default.
• W3100891808 hasConcept C126322002 @default.
• W3100891808 hasConcept C143998085 @default.
• W3100891808 hasConcept C159654299 @default.
• W3100891808 hasConcept C197934379 @default.
• W3100891808 hasConcept C203014093 @default.
• W3100891808 hasConcept C2777701055 @default.
• W3100891808 hasConcept C2778375690 @default.
• W3100891808 hasConcept C2780850621 @default.
• W3100891808 hasConcept C2780868878 @default.
• W3100891808 hasConcept C2781182431 @default.
• W3100891808 hasConcept C3875195 @default.
• W3100891808 hasConcept C71924100 @default.
• W3100891808 hasConcept C8891405 @default.
• W3100891808 hasConcept C90924648 @default.
• W3100891808 hasConceptScore W3100891808C111113717 @default.
• W3100891808 hasConceptScore W3100891808C112705442 @default.
• W3100891808 hasConceptScore W3100891808C121608353 @default.
• W3100891808 hasConceptScore W3100891808C126322002 @default.
• W3100891808 hasConceptScore W3100891808C143998085 @default.
• W3100891808 hasConceptScore W3100891808C159654299 @default.
• W3100891808 hasConceptScore W3100891808C197934379 @default.
• W3100891808 hasConceptScore W3100891808C203014093 @default.
• W3100891808 hasConceptScore W3100891808C2777701055 @default.
• W3100891808 hasConceptScore W3100891808C2778375690 @default.
• W3100891808 hasConceptScore W3100891808C2780850621 @default.
• W3100891808 hasConceptScore W3100891808C2780868878 @default.
• W3100891808 hasConceptScore W3100891808C2781182431 @default.
• W3100891808 hasConceptScore W3100891808C3875195 @default.
• W3100891808 hasConceptScore W3100891808C71924100 @default.
• W3100891808 hasConceptScore W3100891808C8891405 @default.
• W3100891808 hasConceptScore W3100891808C90924648 @default.
• W3100891808 hasLocation W31008918081 @default.
• W3100891808 hasOpenAccess W3100891808 @default.
• W3100891808 hasPrimaryLocation W31008918081 @default.
• W3100891808 hasRelatedWork W10690345 @default.
• W3100891808 hasRelatedWork W11031267 @default.
• W3100891808 hasRelatedWork W11928235 @default.
• W3100891808 hasRelatedWork W15258700 @default.
• W3100891808 hasRelatedWork W17437393 @default.
• W3100891808 hasRelatedWork W17910342 @default.
• W3100891808 hasRelatedWork W17951593 @default.
• W3100891808 hasRelatedWork W19072084 @default.
• W3100891808 hasRelatedWork W19887974 @default.
• W3100891808 hasRelatedWork W2065971 @default.
• W3100891808 isParatext "false" @default.
• W3100891808 isRetracted "false" @default.
• W3100891808 magId "3100891808" @default.
• W3100891808 workType "article" @default.